ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.

Moral, John Alec

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. [electronic resource] - Nature 03 2020 - 130-135 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1476-4687

10.1038/s41586-020-2015-4 doi


Animals
Carcinoma, Pancreatic Ductal--drug therapy
Dendritic Cells--immunology
Female
Humans
Immunity, Innate--immunology
Immunotherapy
Interleukin-33--immunology
Lymphocyte Activation
Lymphocytes--immunology
Male
Mice
Mice, Inbred C57BL
Pancreatic Neoplasms--drug therapy
Programmed Cell Death 1 Receptor--antagonists & inhibitors
T-Lymphocytes--immunology